I commend Professor VanderWeele for providing a lucid description of the "surrogate paradox" and, through it, a comprehensive discussion of the current state of thinking about surrogate endpoints, their function in experimental studies, and the various approaches devised to give them formal underpinnings.
structural parameters α, β, γ and δ.
The surrogate paradox will be exhibited when the effect of treatment A on the surrogate S (3) is positive, S and Y are positively correlated (2), but the effect of A on Y is negative (1), that is, when the structural parameters satisfy:
Clearly, for any γ > 0 and any β, one can find α sufficiently negative and δ sufficiently positive so as to satisfy (4) and (5). Moreover, even for the unconfounded case, δ = 0, shown in Fig. 1(b) , the three inequality can be satisfied with β > 0 and α sufficiently negative, namely, α < −βγ. We conclude that the surrogate paradox may occur in very common models; it does not require confounding, nor interaction or heterogeneity. It requires only that the direct effect of A on Y be sufficiently negative for the paradox to surface. This of course is an unlikely situation in practice. A treatment that has such a negative direct effect on outcome would rarely be a candidate for surrogacy analysis. In practice, the paradox is more likely to take place under confounding conditions (δ > 0) where even a positive α and a negative β will permit it to surface.
We now address the question of why we cannot pose the avoidance of the surrogate paradox, namely, the positivity of all quantities on the left hand side of Eqs. (1)- (3) as a formal definition of a "good" surrogate. Indeed, unlike Simpson's paradox, which stems from a misinterpretation of statistical data (Pearl, 2009, Ch. 6) , negating the surrogate paradox expresses precisely what we expect a "good" surrogate to do. It is expected to provide a good prediction of outcome, once it is found to be positively affected by the treatment. Why, then, have researchers labored to define "good" surrogates using fancy formalisms such as "indirect effect," "principal strata, 2 " or "proportion-mediated" (Joffe and Green, 2009 ) instead of constraining Eqs. (1)- (3) with the proper inequalities?
The reason, I believe, is that definitions are expected to be formulated in terms of the knowledge available to the investigator at the time of the study, and this knowledge consists of qualitative understanding of the model's structure prior to seeing the data, or quantitative assessments of the parameters after examining the data. Eqs. (4)- (6) show that structural knowledge is not sufficient to protect us from the paradox. The paradox may surface even when α = 0 (strong surrogacy) or β = 0. About the only structural condition to prevent the paradox is α = δ = 0, which amounts to perfect mediation (Prentice, 1989) . As to quantitative protection from the paradox, the confounding model of Fig. 1 does not permit the identification of α, β, and δ, or, in the nonparametric case, of direct and indirect effects.
Another important consideration is robustness. Pearl and Bareinboim (2011) argued that good prediction of the effect of A on Y should not be the sole criterion for judging surrogacy, but must be accompanied with a requirement of robustness. Let us imagine two studies. In the first, we measure the effects of A on both S and Y and confirm that S is a good surrogate, that is, knowing the effect of treatment on S allows prediction of the effect of treatment on the outcome. Once S is proclaimed a "surrogate," it invites efforts to find direct means of controlling S. For example, if cholesterol level (S) is found to be a predictor of heart disease in a long run (Y ), drug manufacturers would rush to offer cholesterol-reducing substances for public consumption. As a result, both the prior P (S = s) and the treatment-dependent probability P (S = s|A = a) would undergo a change. For S to be a good surrogate, we should be able to re-assess the effect of the treatment E(Y 1 −Y 0 ) in a new population in which the effect of treatment on S has changed, and in which access to Y is no longer available. Instead, we have an experiment to assess the new value of E(S 1 −S 0 ). Pearl and Bareinboim (2011) have shown that, if we assume that the disparity between the two populations lies only in the difference in E(S 1 −S 0 ) (the surrogate's susceptibility to treatment) the effect of treatment on the outcome under the new conditions can still be estimated from the two studies, provided S and Y are not confounded.
